Artwork

Dr. Bob Gabbay - The Future of GLP-1s

Future of Fitness

0-10 subscribers

published

iconShare
 
Manage episode 484745007 series 1757122
Content provided by Eric Malzone. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Eric Malzone or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this conversation, Dr. Bob Gabbay discusses the evolution and impact of GLP-1 medications on weight loss and fitness. He highlights the importance of integrating lifestyle changes with medication, the current state of GLP-1 treatments, and the role of fitness professionals in supporting patients. The discussion also touches on the future of healthcare, technological innovations, and the potential of exercise mimetics. Takeaways
  • GLP-1 medications have been around for 20 years but have recently exploded in popularity.
  • The evolution of GLP-1 treatments has led to significant weight loss results, with newer medications achieving up to 22% weight loss.
  • Lifestyle changes remain crucial for individuals using GLP-1 medications, complementing their effects.
  • Statistics show that one in eight Americans have tried GLP-1 medications, but many stop within a year due to side effects or expectations.
  • Common side effects of GLP-1 medications include nausea and gastrointestinal issues, with muscle wasting being a significant concern.
  • Fitness professionals have a vital role in educating and supporting patients using GLP-1 medications.
  • Technological innovations, such as AI and digital health tools, are transforming healthcare and patient engagement.
  • The future of healthcare may see a greater integration of fitness professionals into the healthcare ecosystem.
  • Exercise mimetics are being explored as a way to stimulate muscle growth without traditional exercise.
  • By 2030, there is hope for improved access to GLP-1 medications and a shift in societal attitudes towards treating obesity as a disease.

LINKS: https://goteamup.com/

https://podcastcollective.io/

https://egym.com/int

  continue reading

518 episodes